Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Age-Related Macular Degeneration | Disease Landscape and Forecast | G7 | 2016
In late age-related macular degeneration (AMD), vision deficits are noticeable, are often debilitating, and can be a precursor to blindness. The availability of vascular endothelial growth factor (…
Wet Age-Related Macular Degeneration | Treatment Algorithms | Claims Data Analysis | US | 2015
Wet age-related macular degeneration (AMD) is characterized by abnormal growth of blood vessels under the retina, leading to optic nerve damage, visual impairment, and potentially blindness…
Wet Age-Related Macular Degeneration (Current and Future Uptake of Anti-VEGF Agents for Wet AMD) | Physician & Payer Forum | China | 2015
How Does Cost versus Dosing Impact Prescriber Preferences and Payer Policy? The prevalence of age-related macular degeneration (AMD) is increasing with the aging population in China. Therapies…
Wet Age-Related Macular Degeneration (Current and Future Uptake of Anti-VEGF Agents for Wet AMD) | Physician & Payer Forum | Brazil/Mexico | 2015
How Does Cost Versus Dosing Impact Prescriber Preferences and Payer Policy? Agents that target vascular endothelial growth factor (VEGF) have expanded the treatment armamentarium in Brazil and…
Wet AMD (The Anti-VEGF Era and Beyond in Wet AMD: The Impact of Clinical Attributes and Market Access Status on Current and Future Prescribing Decisions Among Retinal Specialists) | Physician & Payer Forum | EU5 | 2014
Treatment for the wet (exudative, neovascular) form of age-related macular degeneration (AMD) in Europe is characterized by several current therapies targeting vascular endothelial growth factor (…
